Literature DB >> 21813597

Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone.

Sita Awasthi1, John M Lubinski, Carolyn E Shaw, Shana M Barrett, Michael Cai, Fushan Wang, Michael Betts, Susan Kingsley, Daniel J Distefano, John W Balliet, Jessica A Flynn, Danilo R Casimiro, Janine T Bryan, Harvey M Friedman.   

Abstract

Attempts to develop a vaccine to prevent genital herpes simplex virus 2 (HSV-2) disease have been only marginally successful, suggesting that novel strategies are needed. Immunization with HSV-2 glycoprotein C (gC-2) and gD-2 was evaluated in mice and guinea pigs to determine whether adding gC-2 to a gD-2 subunit vaccine would improve protection by producing antibodies that block gC-2 immune evasion from complement. Antibodies produced by gC-2 immunization blocked the interaction between gC-2 and complement C3b, and passive transfer of gC-2 antibody protected complement-intact mice but not C3 knockout mice against HSV-2 challenge, indicating that gC-2 antibody is effective, at least in part, because it prevents HSV-2 evasion from complement. Immunization with gC-2 also produced neutralizing antibodies that were active in the absence of complement; however, the neutralizing titers were higher when complement was present, with the highest titers in animals immunized with both antigens. Animals immunized with the gC-2-plus-gD-2 combination had robust CD4+ T-cell responses to each immunogen. Multiple disease parameters were evaluated in mice and guinea pigs immunized with gC-2 alone, gD-2 alone, or both antigens. In general, gD-2 outperformed gC-2; however, the gC-2-plus-gD-2 combination outperformed gD-2 alone, particularly in protecting dorsal root ganglia in mice and reducing recurrent vaginal shedding of HSV-2 DNA in guinea pigs. Therefore, the gC-2 subunit antigen enhances a gD-2 subunit vaccine by stimulating a CD4+ T-cell response, by producing neutralizing antibodies that are effective in the absence and presence of complement, and by blocking immune evasion domains that inhibit complement activation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21813597      PMCID: PMC3187515          DOI: 10.1128/JVI.00849-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  65 in total

1.  Effector CD4+ T-cell involvement in clearance of infectious herpes simplex virus type 1 from sensory ganglia and spinal cords.

Authors:  Alison J Johnson; Chin-Fun Chu; Gregg N Milligan
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

2.  A replication-competent, neuronal spread-defective, live attenuated herpes simplex virus type 1 vaccine.

Authors:  Elizabeth E Brittle; Fushan Wang; John M Lubinski; Ralph M Bunte; Harvey M Friedman
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

3.  Cell surface expression of the vaccinia virus complement control protein is mediated by interaction with the viral A56 protein and protects infected cells from complement attack.

Authors:  Natasha M Girgis; Brian C Dehaven; Xin Fan; Kendra M Viner; Mohammad Shamim; Stuart N Isaacs
Journal:  J Virol       Date:  2008-02-20       Impact factor: 5.103

Review 4.  Genital herpes.

Authors:  Rachna Gupta; Terri Warren; Anna Wald
Journal:  Lancet       Date:  2007-12-22       Impact factor: 79.321

5.  Human factor H interacts selectively with Neisseria gonorrhoeae and results in species-specific complement evasion.

Authors:  Jutamas Ngampasutadol; Sanjay Ram; Sunita Gulati; Sarika Agarwal; Chongqing Li; Alberto Visintin; Brian Monks; Guillermo Madico; Peter A Rice
Journal:  J Immunol       Date:  2008-03-01       Impact factor: 5.422

6.  Immunization with HSV-1 glycoprotein C prevents immune evasion from complement and enhances the efficacy of an HSV-1 glycoprotein D subunit vaccine.

Authors:  Sita Awasthi; John M Lubinski; Harvey M Friedman
Journal:  Vaccine       Date:  2009-09-15       Impact factor: 3.641

7.  Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs.

Authors:  Yo Hoshino; Lesley Pesnicak; Kennichi C Dowdell; Peter D Burbelo; David M Knipe; Stephen E Straus; Jeffrey I Cohen
Journal:  J Infect Dis       Date:  2009-10-01       Impact factor: 5.226

8.  Influenza A virus M1 blocks the classical complement pathway through interacting with C1qA.

Authors:  Junjie Zhang; Gang Li; Xiaoling Liu; Zengfu Wang; Wenjun Liu; Xin Ye
Journal:  J Gen Virol       Date:  2009-08-05       Impact factor: 3.891

9.  Complement-dependent enhancement of CD8+ T cell immunity to lymphocytic choriomeningitis virus infection in decay-accelerating factor-deficient mice.

Authors:  Chongyun Fang; Takashi Miwa; Hao Shen; Wen-Chao Song
Journal:  J Immunol       Date:  2007-09-01       Impact factor: 5.422

10.  Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells.

Authors:  Michael G Strainic; Jinbo Liu; Danping Huang; Fengqi An; Peter N Lalli; Nasima Muqim; Virginia S Shapiro; George R Dubyak; Peter S Heeger; M Edward Medof
Journal:  Immunity       Date:  2008-03-06       Impact factor: 31.745

View more
  43 in total

1.  Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread.

Authors:  Sita Awasthi; Elizabeth E Zumbrun; Huaxin Si; Fushan Wang; Carolyn E Shaw; Michael Cai; John M Lubinski; Shana M Barrett; John W Balliet; Jessica A Flynn; Danilo R Casimiro; Janine T Bryan; Harvey M Friedman
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

2.  DNA vaccine expressing herpes simplex virus 1 glycoprotein C and D protects mice against herpes simplex keratitis.

Authors:  Li-Li Dong; Ru Tang; Yu-Jia Zhai; Tejsu Malla; Kai Hu
Journal:  Int J Ophthalmol       Date:  2017-11-18       Impact factor: 1.779

3.  A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.

Authors:  Sita Awasthi; Gregory G Mahairas; Carolyn E Shaw; Meei-Li Huang; David M Koelle; Christine Posavad; Lawrence Corey; Harvey M Friedman
Journal:  J Virol       Date:  2015-06-03       Impact factor: 5.103

4.  Antibody responses to crucial functional epitopes as a novel approach to assess immunogenicity of vaccine adjuvants.

Authors:  Sita Awasthi; Lauren M Hook; Gokul Swaminathan; Tina M Cairns; Benjamin Brooks; Jeffrey S Smith; Noah T Ditto; Marian E Gindy; Andrew J Bett; Amy S Espeseth; Gary H Cohen; Harvey M Friedman
Journal:  Vaccine       Date:  2019-05-29       Impact factor: 3.641

5.  Dissection of the antibody response against herpes simplex virus glycoproteins in naturally infected humans.

Authors:  Tina M Cairns; Zhen-Yu Huang; J Charles Whitbeck; Manuel Ponce de Leon; Huan Lou; Anna Wald; Claude Krummenacher; Roselyn J Eisenberg; Gary H Cohen
Journal:  J Virol       Date:  2014-08-20       Impact factor: 5.103

6.  Trivalent Glycoprotein Subunit Vaccine Prevents Neonatal Herpes Simplex Virus Mortality and Morbidity.

Authors:  Chaya D Patel; Sean A Taylor; Jesse Mehrbach; Sita Awasthi; Harvey M Friedman; David A Leib
Journal:  J Virol       Date:  2020-05-18       Impact factor: 5.103

7.  Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs.

Authors:  Sita Awasthi; John W Balliet; Jessica A Flynn; John M Lubinski; Carolyn E Shaw; Daniel J DiStefano; Michael Cai; Martha Brown; Judith F Smith; Rose Kowalski; Ryan Swoyer; Jennifer Galli; Victoria Copeland; Sandra Rios; Robert C Davidson; Maya Salnikova; Susan Kingsley; Janine Bryan; Danilo R Casimiro; Harvey M Friedman
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

Review 8.  The challenge of developing a herpes simplex virus 2 vaccine.

Authors:  Lesia K Dropulic; Jeffrey I Cohen
Journal:  Expert Rev Vaccines       Date:  2012-12       Impact factor: 5.217

9.  Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes.

Authors:  Sita Awasthi; Lauren M Hook; Norbert Pardi; Fushan Wang; Arpita Myles; Michael P Cancro; Gary H Cohen; Drew Weissman; Harvey M Friedman
Journal:  Sci Immunol       Date:  2019-09-20

10.  Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine.

Authors:  Sita Awasthi; Robert B Belshe; Harvey M Friedman
Journal:  J Infect Dis       Date:  2014-03-20       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.